Blueprint
 
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 18 December 2017
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
                                                                                                                                                                                    GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882   
 
b)
Nature of the transaction
Sale of 20,000 Ordinary shares on 18 December 2017 at a price of £13.1044.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.1044
20,000
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2017-12-18
f)
Place of the transaction
 
London Stock Exchange, Main Market (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs S Vallance
b)
Position/status
PCA of Dr P J T Vallance (President, R&D)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Sale of 32,974 Ordinary shares on 18 December 2017 at a price of £13.0911
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0911
32,974
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
  
 
e)
Date of the transaction
2017-12-18
f)
Place of the transaction
 
London Stock Exchange, Main Market (XLON)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: December 18, 2017 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc